Abstract
Trikafta® ETI is a triple therapy cystic fibrosis transmembrane conductance regulator (CFTR) medication available in Australia for children over twelve years of age since April 1, 2022. Although it has been found to be a highly effective in the treatment of CF, some individuals require a reduced dose due to drug-drug interactions or significant co-morbidities.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
